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Background: Many low and middle-income countries are experiencing colliding epidemics of chronic infectious
(ID) and non-communicable diseases (NCD). As a result, the prevalence of multiple morbidities (MM) is rising.
Methods: We conducted a study to describe the epidemiology of MM in a primary care clinic in Khayelitsha. Adults
with at least one of HIV, tuberculosis (TB), diabetes (DM), and hypertension (HPT) were identified between Sept
2012-May 2013 on electronic databases. Using unique patient identifiers, drugs prescribed across all facilities in the
province were linked to each patient and each drug class assigned a condition.
Results: These 4 diseases accounted for 45% of all prescription visits. Among 14364 chronic disease patients, HPT
was the most common morbidity (65%). 22.6% of patients had MM, with an increasing prevalence with age; and a
high prevalence among younger antiretroviral therapy (ART) patients (26% and 30% in 18-35 yr and 36–45 year age
groups respectively). Among these younger ART patients with MM, HPT and DM prevalence was higher than in
those not on ART.
Conclusions: We highlight the co-existence of multiple ID and NCD. This presents both challenges (increasing
complexity and the impact on health services, providers and patients), and opportunities for chronic diseases
screening in a population linked to care. It also necessitates re-thinking of models of health care delivery and
requires policy interventions to integrate and coordinate management of co-morbid chronic diseases.
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The concept of multi-morbidity (MM), defined as the co-
existence of more than one chronic condition in one per-
son, is well recognized, usually within the context of older
age [1]. Patients with MM have increased utilization of
health care, a reduced quality of life and poorer health out-
comes [1-4]. A recent systematic review of MM patterns
described a non-random pattern of MM for which com-
mon pathophysiological mechanisms underlie each disease
constellation [1]. However all studies in this review were* Correspondence: tolullah.oni@uct.ac.za
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age populations, and included only non-communicable
diseases (NCD). In low- and middle-income countries
(LMIC), with burgeoning urbanisation, not only is the
prevalence of NCD increasing, it is occurring alongside
chronic infectious diseases. Thus patterns of MM will
differ.
South Africa is the most urbanised country in sub-
Saharan Africa with 62% of the country’s population liv-
ing in cities [1, 5]. The rapid and unplanned nature of
this demographic shift affects life choices and opportun-
ities; contributing to epidemiological transition with an
increase in unhealthy dietary patterns, a decrease in
physical activity and a rising NCD burden [2-4, 6, 7].
South Africa has the highest burden of hypertension
(HPT) in the >50 years old population and among theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Saharan Africa [1, 8, 9]; this is predicted to increase fur-
ther over the next few decades. Against this background,
the burden of HIV and tuberculosis (TB) remain high.
Effective antiretroviral therapy (ART), in widespread use
in South Africa since 2005/6 has resulted in increasing
survival and ageing among HIV-infected persons and an
accompanying rise in NCD co-morbidities in this sub-
group [10, 11]. Furthermore, the premature ageing effect
of HIV will likely further contribute to multiple morbid-
ities in the population [12], at younger ages than de-
scribed in low HIV-burden settings. The morbidity and
mortality rates for NCD, HIV and TB in South Africa
disproportionately affects poor people with the NCD
burden fuelled by a high prevalence of obesity, which af-
fects 40% of the adult female population [7]. However,
little is known about the prevalence and patterns of
MM in South Africa and other LMIC, where the preva-
lence of NCD is rising alongside established HIV/TB
epidemics.
A better understanding of the patterns of chronic in-
fectious and non-communicable disease multimorbidity
(MM) in LMIC is therefore required to develop strat-
egies to prevent and better manage these co-existing and
interacting conditions. A study conducted in the UK
comparing measures of MM found the number of pre-
scribed drugs to be the most powerful measure for pre-
dicting future healthcare utilization and second most
powerful for predicting mortality [13]. We aimed to use
routine data from a public health programme to explore
the distribution of chronic diseases and patterns of HIV,
TB, and NCD MM in adults who have received care and
treatment in a public clinic.
Methods
Setting: We conducted a cross-sectional study in Michael
Mapongwana clinic, a primary care health facility in
Khayelitsha, an informal township near Cape Town with a
population of >500 000 predominantly black Africans.
This study was approved by the University of Cape Town,
Faculty of Health Sciences Human Research Ethics com-
mittee (HREC Ref no: 493/2014).
Data Source: Data on treatment prescriptions were ex-
tracted from two routine electronic databases. Patients
who are considered stable on chronic disease medication
receive their monthly prescriptions through the Chronic
Disease Dispensing unit (CDU), an outsourced centralised
unit that collects prescriptions for stable chronic patients
from health facilities, dispenses the medicines, and returns
them to the facilities which the patients attend, packaged
in tamper-proof parcels. A record of medicines dispensed
is kept on a database that is sent to the Western Cape
Department of Health Data Repository on a monthly basis.
The second database used is the electronic prescriptionsystem that manages pharmacy prescriptions electronic-
ally. This system has been in use across secondary and
tertiary-level hospitals in the Western Cape province
for >10 years and enables pharmacy records linked to an
individual patient to be accessible across hospitals. Roll out
of this system in primary care clinics began in September
2012 in Michael Mapongwana clinic in Khayelitsha. This
database captures chronic disease patients not receiving
medicines through the CDU, including sub-optimally man-
aged chronic disease patients. Every patient accessing
health care in the public clinics and hospitals is ascribed a
unique patient master index (PMI) that serves to longitu-
dinally link prescriptions across different databases and
health care facilities.
Persons prescribed medicines for at least one of the four
most prevalent chronic diseases (HIV, TB, diabetes (DM),
HPT) were identified from the electronic pharmacy and
CDU databases from September 2012, when the electronic
pharmacy database was launched, to May 2013. This time
period was selected to capture 6-monthly prescriptions over
a 9-month period from the electronic pharmacy databases.
The anonymised dataset extracted included age, sex, and
medications prescribed at all consultations over the study
period. Using the PMI, medicines prescribed across all
health facilities in the province were linked to each patient.
Each drug class was assigned a condition based on South
African prescription guidelines: HPT defined as a prescrip-
tion of at least one of hydrochlorthiazide, enalapril, or
amlodipine; DM defined as a prescription of metformin, gli-
clazide, glibenclamide, or insulin; HIV/ART defined as pre-
scription of ART; TB defined as prescription of rifampicin,
isoniazid, or pyrazinamide. MM was defined as receiving
medication for two or more of the 4 morbidities measured.
Statistical analysis: Descriptive analyses were represented
using percentages, frequencies, and tabulation. Age cat-
egories 18–35, 35–45, 46–55, >55 were used to explore
the age-distribution of chronic diseases and MM; stratified
by sex using the λ2 test. The prevalence of MM was also
calculated stratified by HIV/ART status, into ART and
non-ART (HIV status unknown) groups, across the differ-
ent age groups. Co-morbidity patterns across the individ-
ual chronic diseases were examined. The λ2 test was used
to measure differences in the prevalence of chronic dis-
eases and MM. The Shapiro-Wilk test was used to test for
normality and the Kruskal Wallis test used to test for stat-
istical significance of non-parametric continuous variables.
Significance testing was done using 2-sided p-values and
95% confidence intervals. All data were analysed using
STATA 12.0 (StataCorp, College Station, TX, USA).
Role of funding sources: The funders had no role in
the design, collection, analysis, and writing of this manu-
script. TO confirms that she had full access to all data
and had final responsibility for the decision to submit
the manuscript for publication.
Figure 1 Distribution of HPT, DM, HIV/ART, and TB, stratified by
gender across age groups among patients with prescriptions for at
least one of HPT, DM, HIV/ART, and TB. Key: HPT Hypertension; DM
Diabetes; ART Antiretroviral therapy; TB Tuberculosis; MM Multimorbidity.
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A. Baseline characteristics and descriptive analysis
A total of 32 474 patients attended the clinic and received
at least one prescription between Sept 2012 and May
2013. Of these, 14 700 (45%) were consultations for HIV,
TB, DM or HPT. Three hundred and thirty six of the 14
700 patients were aged <18 years and excluded from fur-
ther analysis. The final study population sample size was
14 364 adults. The age distribution of the study population
showed that while 71% of the total population were fe-
male, the male: female ratio increased with increasing age
(Table 1) with a higher proportion of male: female ratio in
the 46–55 and >55 years age groups. The median age was
46 years (interquartile range (IQR) 36–56) overall; 46 years
(IQR 35–55) in females and 48 years (IQR 39–57) in
males. The prevalence of HPT, DM, HIV and TB in the
study population, overall and stratified by gender is sum-
marized in Table 1. As shown in Figure 1 there was an in-
crease in the prevalence of NCD (HPT and DM) with
increasing age. Overall, the prevalence of HPT, DM and
TB was higher in male versus female participants. How-
ever, analysed by gender, it was evident that younger fe-
males had a higher prevalence of DM (18–35 age group;
7.5% vs. 5.8%, p = 0.015) and HPT (26–35 (9.2% vs. 8.5%,
p < 0.0001), 36–45 (18.7% vs. 16.8%, p < 0.0001), and 46–
55 (34.6% vs. 31.2%, p < 0.0001) age groups). Men >55 had
a higher prevalence of HPT (43.5% vs. 37.5%, p < 0.001)
and HIV/ART (8.1% vs. 3.2%, p < 0.0001).
The distribution of TB and HIV/ART prevalence also
differed by gender. Females in the 18–35 age group had
a higher HIV/ART (48% vs. 22.8%, p < 0.0001), and TB
(46.6% vs. 31.8%, p < 0.0001) prevalence compared to
men. By contrast, male patients aged 36–45 and 46–55
had a higher prevalence of HIV/ART (45.1% vs. 35.4%,
p = 0.021; and 24% vs. 13.5%, p < 0.0001, respectively) andTable 1 Baseline characteristics, overall and stratified by gender
Female% Male% Total%
N = 10231 N = 4119 N = 14350*
(95% C.I.) (95% C.I.) (95% C.I.)
Age 18-35 24.4 (23.5-25.2) 14.0 (12.9-15.1) 21.4 (20.7-22.1)
36-45 24.8 (23.9-25.6) 26.6 (25.3-28) 25.3 (24.6-26.0)
46-55 26.1 (25.3-27.0) 28.4 (27.1-29.8) 26.8 (26.1-27.5)
>55 24.7 (24.0-25.7) 31.0 (29.6-32.4) 26.6 (25.9-27.3)
Total N = 10231 N = 4119
Median age Years (IQR) 46 (35–55) 48 (39–57) 46 (36–56)
Hypertension 63.9 (63.0-64.9) 66.3 (64.8-67.7) 64.6 (63.8-65.4)
Diabetes 17.7 (17.0-18.5) 19.6 (18.4-20.8) 18.3 (17.6-18.9)
HIV/ART 39.5 (38.5-40.4) 35.7 (34.3-37.2) 38.4 (37.6-39.2)
Tuberculosis 2.3 (2.1-2.6) 3.7 (3.2-4.4) 2.7 (2.5-3.0)
*Gender assignment missing for 14 patients.
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p = 0.004, respectively) compared to females (Figure 1).
B. Burden and distribution of multimorbidity
The overall prevalence of MM was 22.6% (n = 3246) with
no significant difference between sexes. The prevalence
of MM increased with increasing age. Among patients
with MM, 94% had 2 morbidities, the most common
combination of which was HPT and DM (Figure 2). Five
percent had 3 conditions of which HPT, DM, and HIV
were the most common. There was no significant differ-
ence in the proportion of MM patients with double,
triple, or quadruple morbidities between sexes (data not
shown). The overall age distributions were similar, with
the highest prevalence in the 36–45 and 46–55 age
groups, across these MM categories (data not shown).
Although the prevalence of MM was highest in DM pa-
tients (88.1%), the number of patients with MM is high-
est in HPT patients (32.3% of 9 279 patients) due to the
high overall prevalence of HPT (65%) of the sample
population. The co-morbidity pattern differed across the
4 diseases (Figure 3). Among DM MM patients, 97%
had HPT as a co-morbidity, while 75% of HPT MM pa-
tients were on DM treatment. Among TB MM patients
(81.1% of all TB patients), HIV/ART was the most com-
mon co-morbidity (followed by HPT and DM); while
HIV/ART MM patients were most commonly receiving
HPT treatment (Figure 3).
C. Age-specific multimorbidity and the effect of HIV
The prevalence of MM among younger HIV-infected pa-
tients in the 18–35 and 36–45 age groups was higherFigure 2 Patterns and distribution of single, double and triple morbidthan in their counterparts not on ART, but not in
the >55 age group, where the pattern was reversed; al-
though the prevalence of HIV/ART in this age-group
was low (Figure 4). Stratified by gender, there was a dif-
ference in the age distribution of HIV/ART MM patients
with a higher MM prevalence in the youngest the 18–35
age group in females versus male patients (Figure 4;
p = 0.017). By contrast, the peak in MM for male ART
patients occurred in the older 46–55 age group. Further
investigation of the pattern of co-morbid conditions in
HIV/ART patients with MM versus MM patients not on
ART (HIV status unknown) in the 18–35 years age cat-
egory revealed a higher prevalence of HPT (19.7% (95%
confidence interval (C.I.) 3.1-4.7%) vs. 3.8% (95% C.I.
17.2-22.6%)) and DM (12.3% (95% C.I. 8.3-18.0%) vs.
3.8% (95% C.I. 3.0-4.6%)) in ART MM patients. A similar
pattern for HPT (30.2% (95% C.I. 27.2-33.45%) vs. 14.6%
(95% C.I. 13.1-16.1%)) and DM (25.8% (95% C.I. 20.0-
32.7%) vs. 14.3% (95% C.I. 12.9-15.9%)) was found among
MM patients in the 36–45 years age category (Figure 5).
In the next age group, 46–55 years, DM co-morbidity
remained higher in HIV-infected persons on ART than
the non ART group (43.8% (95% C.I. 36.7-51.2%) versus
32.8% (95% C.I. 30.9-34.8%)) but the prevalence of HPT
co-morbidity did not differ between the two groups.
Discussion
This study examined co-morbidity patterns in a cohort
of patients receiving at least one prescription for one of
4 diseases over a 9-month period, and has a number of
major findings. Firstly, a quartet of chronic diseases
accounted for 45% of all consultations in a communityities.
Figure 3 Proportion of patients with multimorbidity among 32 474 patients who attended the clinic and received any prescription;
and the distribution of morbidities among patients with prescriptions for at least one of HPT, DM, HIV/ART, and TB. Key: HPT
Hypertension; DM Diabetes; HIV/ART HIV infected patients on antiretroviral therapy; TB Tuberculosis; MM Multimorbidity.
Figure 4 Distribution of non-HIV morbidities among MM
patients (n = 3246), stratified by sex and HIV/ART groups.
Error bars show 95% confidence intervals.
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low socioeconomic status in Cape Town. Secondly, we
found a 22.6% prevalence of MM among chronic disease
patients and an associative pattern of MM, with HPT and
DM often co-existing. Furthermore HPT was the most
common co-morbidity in both HIV/ART and DM pa-
tients. Thirdly, we demonstrated that while HIV/ART was
the most common co-morbidity among TB patients, 37%
and 12% of multi-morbid TB patients were also on treat-
ment for HPT and DM respectively. Fourthly, we found a
high prevalence of MM in younger patients on ART (26%
and 30% in 18–35 year and 36–45 year age groups re-
spectively). Lastly, we showed that among these younger
HIV/ART patients with MM, HPT and DM prevalence
was significantly higher than patients in the same age
groups who were not on ART.
Our results reveal a very high prevalence of HPT among
chronic disease patients. This is congruent with national
data that shows a high overall prevalence of HPT in the
general population and that HPT is the commonest
reason for attendance of primary health clinics in South
Africa [14]. A national, population-based study of persons
50 years and older in South Africa reported HPT preva-
lence of 77.3% [15]. It is noteworthy that HPT was the
most common co-morbidity in both DM and HIV/ART
MM patients. It was not surprising that 88% of all DM
MM patients were also on treatment for HPT; DM pa-
tients are routinely screened for HPT in this setting. On
the other hand, blood pressure screening is not currently
routine in the management of HIV/ART and TB patients.
Figure 5 Distribution of HPT and DM across age groups comparing HIV/ART MM patients to MM patients not on ART (HIV status unknown).
Error bars show 95% confidence intervals.
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were on treatment for DM suggesting that HPT patients
should also routinely be screened for DM, which is not
current local practice. Our results are comparable to data
from high-income settings. A recent study from Ireland
examined co-morbidity patterns (including hypertension,
heart disease, arthritis, depression, and chronic lung dis-
ease) and reported that 90% of a cohort of DM patients
had another morbidity and 66% had HPT [16]. However,
90% of study participants in this study were >50 years old
and HIV status was not documented.
Among TB patients with other chronic disease co-
morbidities, the prevalence of HIV co-infection was high.
This was an expected result as the HIV/TB co-infection
rate in this local setting has previously been estimated as
67% [17]. Our data demonstrated that in addition to HIV,
TB patients also have a significant prevalence of HPT and
DM. A study in Brazil examined chronic disease multi-
morbidity in TB patients. Whilst they reported a lower
prevalence of MM than we found (1.14%; higher in older
age groups), their results highlighted the importance of
MM as they demonstrated that death from causes other
than TB was higher, and cure rates lower in TB-MM pa-
tients [18]. While these conditions may co-exist, some
interact, through either shared risk factors or pathophy-
siology; or one disease influencing susceptibility and
outcomes of the other. For example, DM is associated
with a 2–3 fold higher risk of TB [19]. Further research istherefore required to evaluate the proportion of TB cases
attributable to DM in this high HIV/TB/DM setting.
MM was lower overall in HIV/ART patients compared
to patients not on ART with unknown HIV status. How-
ever when stratified by age, we noted that in the younger
age groups (18–35 and 36–45 years), MM was higher in
HIV/ART patients, in particular, there was a higher preva-
lence of HPT, DM and TB. One possible reason for this
difference is the previously reported association between
HIV/ART and premature and accelerated ageing [20]. This
could also be due to increased awareness of NCD among
HIV/ART patients, and possibly increased access to NCD
screening in ART clinics. Obesity in HIV-infected patients
is an emerging issue in South Africa; with some antiretro-
viral drugs, such as non-nucleoside reverse transcriptase
inhibitors currently in use in South Africa, contributing to
lipodystrophy and truncal obesity, increasing the risk of
DM, HPT, and metabolic syndrome [10, 21]. A study of
MM in HIV-infected patients in the United States found a
prevalence of MM of 65%, with prevalence increasing with
increasing body mass index (BMI) [22]. In the 46–55 age
group, while HPT prevalence was similar between groups,
DM prevalence was higher in the HIV/ART group; pos-
sibly highlighting a previously reported association be-
tween an increased risk of dysglycaemia in HIV-infected
patients on ART [21].
Multimorbidity results in complex disease patterns
that may have multiplicative, and not merely additive,
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patients’ ability to manage their condition and enact be-
havior changes that may be required to improve health.
This increasing complexity impacts on both health ser-
vices, through more intensive health care requirements,
and on health providers, with an increased requirement
for integrated generalist care at the primary care level.
This changing pattern of disease will therefore require
health policy and interventions that differ from trad-
itional vertical approaches and single disease manage-
ment such as integrated management of chronic disease
patients considered to be stable [23]. Although there is
data paucity on the cost benefit of integrated systems,
existing data suggests that integrating chronic disease
services into existing HIV care may improve cost effect-
iveness [24]. For example, established systems for the de-
livery of ART and TB medications could be adapted to
include essential drugs required for NCD management
in order to streamline healthcare delivery and potentially
improve adherence to chronic medications [25]. Similarly,
funding mechanisms that usually fund NCD research
could facilitate further research into integrated manage-
ment building on existing HIV care infrastructure estab-
lished through HIV funding mechanisms such as the
President’s Emergency Plan for AIDS Relief (PEPFAR) [26].
Furthermore the associative patterns of MM described
in this study suggest active bidirectional and targeted
screening for these conditions should be implemented.
Routine active screening is likely to result in an even
higher burden of diagnosed co-morbidities in the short
term, but diagnosis and intervention at an earlier stage
may ultimately result in reduced overall cost. The impact
of active screening on the health care system should
therefore be evaluated. Beyond these direct interactions,
MM and the associated increased complexity could also
influence the psychological state or patients’ beliefs and
values, influencing decision-making and acceptability of
treatment options, and adherence to treatment [27].
Strengths and limitations
A significant strength of this study is the use of the
unique patient identifier number which enabled any
treatment prescribed within the public health system in
the Western Cape province, even if outside the primary
care clinic, to be identified and included in the study.
The availability of linked records in a public sector pri-
mary care setting is rare both within South Africa and
sub-Saharan Africa. This study utilized data from routine
databases of prescribed drugs. Diagnoses could therefore
not be verified. As a result, only patients with diagnosed
chronic diseases receiving treatment for the selected dis-
eases were identified and included in this study. This
could underestimate the prevalence of the individual
conditions and MM. Patients in chronic care for ART,HPT and DM are plausibly more likely than TB patients
to have blood pressure and urine glucose measured over
time due to regular clinic visits where routine observations
include these measurements; while HIV testing is rou-
tinely performed in TB but not HPT and DM clinics.
Therefore ascertainment bias with the potential for under
ascertainment among TB patients could be a factor. Simi-
larly, in the context of high HIV prevalence in this setting,
as emphasized in the methodology, it is important to in-
terpret the HIV stratification within the context of ART
versus non-ART as the ‘non-ART/HIV unknown’ subset
are likely to include HIV-infected patients who have not
been diagnosed or who are not on ART. Another potential
limitation was the use of prescribed drugs as a proxy for
diagnosis. Whilst medications for DM, HIV, and TB are
relatively specific to these diseases, the prescription of
hydrochlorthiazide, enalapril or amlodipine may be pre-
scribed for cardiovascular diseases and may not be specific
to HPT. However, given the high prevalence of HPT of all
chronic diagnoses in primary care [14], and the prescrip-
tion patterns of doctors at the primary care level, we are
confident that this proxy is a valid estimate of HPT. Prior
to this study, to confirm prescription patterns in a primary
care setting, we conducted a folder review of 100 patients
attending another primary care clinic in Khayelitsha and
found that these 3 drugs accounted for all HPT patients
reviewed.
From a health system perspective, despite these limita-
tions, this study highlights the significant burden of MM
among patients receiving chronic disease care at the pri-
mary health care level.
Conclusions
We demonstrated a high prevalence of chronic infectious
and non-communicable diseases confirming the epidemio-
logical transition in this peri-urban informal township in
South Africa. This study significantly contributes to know-
ledge about the complex interdependencies in multimor-
bid diseases in South Africa, a middle-income country.
The patterns of MM shown suggest that current models of
health care delivery need to be re-examined and patient-
centred models of integration evaluated including bidirec-
tional screening of commonly co-morbid conditions in
routine clinical practice. Furthermore, research into pos-
sible causal underlying mechanisms where unknown; and
the implications for diagnosis and treatment, adherence,
health outcomes, and capacity for behavior change is
required.
Abbreviations
ID: Infectious Diseases; NCD: Non-communicable diseases; MM: Multiple
morbidities; TB: Tuberculosis; DM: Diabetes; HPT: Hypertension;
ART: Antiretroviral therapy; LMIC: Low and middle-income countries;
CDU: Chronic Disease Dispensing unit; PMI: Patient master index;
IQR: Interquartile range; CI: Confidence interval.
Oni et al. BMC Infectious Diseases  (2015) 15:20 Page 8 of 8Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TO, AB, and NSL were responsible for conception and study design. EY was
responsible for data collection from data sources and contributed to data
analysis. TO was responsible for data analysis, data interpretation and writing
of the manuscript. AB, NMcG, RJW, and NSL contributed to data
interpretation and writing of the manuscript. All authors read and approved
the final manuscript.
Acknowledgments
TO is supported by a Carnegie Corporation Postdoctoral Fellowship, a Harry
Crossley Senior Clinical Fellowship and a Wellcome Trust funded Clinical
Infectious Disease Research Initiative clinical fellow postdoctoral award. NMcG is
supported by a Wellcome Trust fellowship grant (# WT083495MA). AB receives
funding from the Western Cape Department of Health. RJW receives funding
from the Wellcome Trust (WT088316 and 084323), MRC(UK)
(U.1175.02.002.00014.01), European and Developing Countries Clinical Trials
Partnership (IP.07.32080.02), and the European Union (FP7 Health-F3-2012-
305578). NSL receives funding from the Department of Health, Medical Research
Council and National Research Foundation, South Africa. The funders had no
role in the design, collection, analysis, and writing of this manuscript. TO
confirms that she had full access to all data and had final responsibility for the
decision to submit the manuscript for publication.
Author details
1Division of Public Health Medicine, School of Public Health and Family
Medicine, University of Cape Town, Room 2.24, Entrance 5, Falmouth
building Anzio road, Observatory 7925, Cape Town, South Africa. 2Health
Impact Assessment Directorate, Western Cape Department of Health, Cape
Town, South Africa. 3Centre for Infectious Disease Epidemiology Research,
Division of Public Health Medicine, School of Public Health and Family
Medicine, University of Cape Town, Cape Town, South Africa. 4Department of
Medicine, University of Cape Town, Cape Town, South Africa. 5Academic Unit
of Primary Care and Population Sciences, University of Southampton,
Southampton, UK. 6Africa Centre for Health and Population Studies,
University of Kwazulu Natal, Durban, South Africa. 7Department of Medicine,
Imperial College, London W2 1PG, UK. 8Medical Research Council National
Institute of Medical Research, London NW7 1AA, UK. 9Chronic Disease
Initiative for Africa, Cape Town, South Africa.
Received: 9 January 2015 Accepted: 12 January 2015
References
1. Prados-Torres A, Calderón-Larrañaga A, Hancco-Saavedra J, Poblador-Plou B,
van den Akker M. Multimorbidity patterns: a systematic review. J Clin Epidemiol.
2014;67(3):254–66.
2. Booth HP, Prevost AT, Gulliford MC. Impact of body mass index on
prevalence of multimorbidity in primary care: cohort study. Fam Pract.
2014;31(1):38–43.
3. Smith SM, O’Dowd T. Chronic diseases: what happens when they come in
multiples? Br J Gen Pract. 2007;57(537):268–70.
4. Fortin M, Dubois M-F, Hudon C, Soubhi H, Almirall J. Multimorbidity and
quality of life: a closer look. Health Qual Life Outcomes. 2007;5(1):52.
5. World Urbanization Prospects: the 2003 revision. United Nations; 2004 Nov.
Available from: http://www.un.org/esa/population/publications/wup2003/
WUP2003Report.pdf
6. Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D. The
burden of non-communicable diseases in South Africa. Lancet.
2009;374(9693):934–47.
7. South African National Health and Nutrition Examination Survey. Health
sciences research council. 2013. p. 1–7.
8. Lloyd-Sherlock P, Ebrahim S, Grosskurth H. Is hypertension the new HIV
epidemic? Int J Epidemiol. 2014;43(1):8–10.
9. Peer N, Steyn K, Lombard C, Lambert EV, Vythilingum B, Levitt NS. Rising
diabetes prevalence among urban-dwelling black South Africans. PLoS One.
2012;7(9):e43336.
10. Levitt NS, Steyn K, Dave J, Bradshaw D. Chronic noncommunicable diseases
and HIV-AIDS on a collision course: relevance for health care delivery,particularly in low-resource settings–insights from South Africa. Am J Clin
Nutr. 2011;94(6):1690S–6S.
11. Malaza A, Mossong J, Bärnighausen T, Newell M-L. Hypertension and obesity
in adults living in a high HIV prevalence rural area in South Africa. PLoS
One. 2012;7(10):e47761.
12. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic
disease. Lancet. 2013;382(9903):1525–33.
13. Brilleman SL, Salisbury C. Comparing measures of multimorbidity to predict
outcomes in primary care: a cross sectional study. Fam Pract. 2013;30(2):172–8.
14. Mash B, Fairall L, Adejayan O, Ikpefan O, Kumari J, Mathee S, et al. A
morbidity survey of South African primary care. PLoS One. 2012;7(3):e32358.
15. Peltzer K, Phaswana-Mafuya N. Hypertension and associated factors in older
adults in South Africa: cardiovascular topics. Cardiovasc J Afr. 2013;24(3):66–71.
16. Teljeur C, Smith SM, Paul G, Kelly A, O’Dowd T. Multimorbidity in a cohort of
patients with type 2 diabetes. Eur J Gen Pract. 2013;19(1):17–22.
17. Médecins Sans Frontierès. Summary: Khayelitsha Activity Report 2001–2011.
msf.org.za. [cited 2012 Jan 24]. Available from: http://www.msf.org.za/
publication/summary-khayelitsha-activity-report-2001-2011.
18. Reis-Santos B, Gomes T, Macedo LR, Horta BL, Riley LW, Maciel EL.
Prevalence and patterns of multimorbidity among tuberculosis patients in
Brazil: a cross-sectional study. Int J Equity Health. 2013;12(1):61.
19. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active
tuberculosis: a systematic review of 13 observational studies. PLoS Med.
2008;5(7):e152.
20. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature
age-related comorbidities among HIV-infected persons compared with the
general population. Clin Infect Dis. 2011;53(11):1120–6.
21. Dave JA, Lambert EV, Badri M, West S, Maartens G, Levitt NS. Effect of
nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on
dysglycemia and insulin sensitivity in South African HIV-infected patients.
J Acquir Immune Defic Syndr. 2011;57(4):284–9.
22. Kim DJ, Westfall AO, Chamot E, Willig AL, Mugavero MJ, Ritchie C, et al.
Multimorbidity patterns in HIV-infected patients: the role of obesity in
chronic disease clustering. J Acquir Immune Defic Syndr. 2012;61(5):600–5.
23. Oni T, McGrath N, BeLue R, Roderick P, Colagiuri S, May CR, et al. Chronic
diseases and multi-morbidity - a conceptual modification to the WHO ICCC
model for countries in health transition. BMC Publ Health. 2014;14(1):575.
24. Hyle EP, Naidoo K, Su AE, El-Sadr WM, Freedberg KA. HIV, tuberculosis, and
noncommunicable diseases. J Acquir Immune Defic Syndr. 2014;67:S87–95.
25. Narayan KMV, Miotti PG, Anand NP, Kline LM, Harmston C, Gulakowski R, et al.
HIV and noncommunicable disease comorbidities in the era of antiretroviral
therapy: a vital agenda for research in low- and middle-income country
settings. J Acquir Immune Defic Syndr. 2014;67 Suppl 1:S2–7.
26. Vermund SH, Narayan KMV, Glass RI. Chronic diseases in HIV survivors.
Sci Transl Med. 2014;6(241):241ed14–4.
27. Richardson WS, Doster LM. Comorbidity and multimorbidity need to be
placed in the context of a framework of risk, responsiveness, and
vulnerability. J Clin Epidemiol. 2014;67(3):244–6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
